Welcome to our dedicated page for Cavitation Technologies SEC filings (Ticker: CVAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how a green-tech micro-cap converts patents into revenue isn’t easy. Cavitation Technologies’ 10-K is packed with reactor specifications, licensing footnotes, and oilseed price sensitivities, while each 10-Q recalibrates R&D spend and partnership milestones. Add in Form 8-K updates on pilot projects and insider trades and the research pile grows fast. If you’ve ever googled “Cavitation Technologies insider trading Form 4 transactions” or searched for the “Cavitation Technologies quarterly earnings report 10-Q filing,” you know the challenge.
Stock Titan solves it. Our AI ingests every submission to EDGAR within seconds and delivers Cavitation Technologies SEC filings explained simply. You’ll receive Cavitation Technologies Form 4 insider transactions real-time, concise snapshots of each Cavitation Technologies annual report 10-K simplified, and alerts the moment a Cavitation Technologies 8-K material events explained hits the wire. Interactive dashboards surface which patents drove revenue, where cash burn accelerated, and how risk factors evolved—turning understanding Cavitation Technologies SEC documents with AI into a five-minute task.
Need deeper context? Drill into the Cavitation Technologies proxy statement executive compensation to benchmark management pay, or review Cavitation Technologies executive stock transactions Form 4 for buying patterns ahead of new reactor contracts. Side-by-side Cavitation Technologies earnings report filing analysis lets you track margin gains from biodiesel clients across multiple periods. Every filing—10-K, 10-Q, 8-K, S-1 and more—is indexed, summarized, and updated in real time, so you can move from raw disclosure to decisive insight without wading through 300 pages of technical detail.
Cavitation Technologies, Inc. (CVAT) reported fiscal year results showing limited revenue and material operating losses. Revenue for the period was $165,000 while cost of revenue was $1,207,000, producing a gross loss of $1,042,000. Total operating expenses were $1,152,000, including $1,057,000 of general and administrative expenses, resulting in a loss from operations of $987,000. The company recorded an $880,000 gain on patent assignment which was collected in full. As of June 30, 2025 the company had an accumulated deficit of $26,960,000 and management disclosed substantial doubt about the company’s ability to continue as a going concern, while stating available cash to sustain operations through December 2025. Significant concentration: 98% of revenue derived from Desmet Belgium. Shares outstanding totaled 289,156,340.
FAQ
What is the current stock price of Cavitation Technologies (CVAT)?
What is the market cap of Cavitation Technologies (CVAT)?
